Holen Sie sich die Stockscreener-App
6.59
0.90%
-0.06
Handel nachbörslich:
6.59
Exagen Inc Aktie (XGN) Neueste Nachrichten
Exagen Inc. to Participate in Upcoming Investor Conference - The Manila Times
Exagen Inc (XGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exagen Inc (XGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XGN|Exagen Inc|Price:4.390|Chg%:-0.290 - TradingKey
Exagen Inc (XGN) Institutional Confidence - TradingKey
Exagen Inc (XGN) Balance Sheet - TradingKey
Exagen Inc (XGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exagen Inc (XGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exagen Inc (XGN) Income Statement - TradingKey
TradingKey - TradingKey
XGN|Exagen Inc|Price:4.680|Chg%:-0.270 - TradingKey
Exagen Inc (XGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Exagen Inc (XGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Exagen nears break-even with strong revenue gro... - Pluang
Exagen: A Small Diagnostics Company Approaching An Inflection Point (NASDAQ:XGN) - Seeking Alpha
Exagen stock stabilizes as autoimmune testing revenue grows and losses narrow - Ad-hoc-news.de
New Exagen study finds variability in myositis antibody detection methods - Traders Union
Exagen schedules 8:30 a.m. call to review second-quarter results - Stock Titan
ETFs Investing in Exagen, Inc. Stocks - TradingView
Exagen (XGN) Q1 2026 Earnings: EPS Beat Fails to Lift Stock, Revenue Concerns LingerTech Earnings Analysis - dars.gov.et
Exagen Inc. (XGN) Q1 2026 Earnings: Narrower Loss Beats Street Estimates, Yet Shares DeclineFinal Results - dars.gov.et
Exagen Inc focuses on autoimmune diagnostics as investors watch strategy - Ad Hoc News
Exagen Company Profile & Introduction - Moomoo
Exagen Inc. (XGN) Faces Selling Pressure, Testing Key Support at $4.31MFI Divergence - dars.gov.et
XGNExagen Inc Volatility & Greeks - Finviz
Exagen Inc. (XGN) Edges Higher as Stock Consolidates Near Key Support LevelNAAIM Leverage - dars.gov.et
Price to earnings forward of Exagen, Inc. – LS:A2PRXT - TradingView
Enterprise value to EBIT forward of Exagen Inc. – NASDAQ:XGN - TradingView
A2PRXT Forecast — Price Target — Prediction for 2027 - TradingView
Exagen Inc. (XGN) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ResponseSpecial Dividend Alert - dars.gov.et
Price to book forward of Exagen Inc. – NASDAQ:XGN - TradingView
Enterprise value to EBIT forward of Exagen, Inc. – GETTEX:E08A - TradingView
Enterprise value to EBITDA forward of Exagen Inc. – NASDAQ:XGN - TradingView
Price to sales forward of Exagen Inc. – NASDAQ:XGN - TradingView
Price to sales forward of Exagen, Inc. – GETTEX:E08A - TradingView
Enterprise value to revenue forward of Exagen Inc. – NASDAQ:XGN - TradingView
Enterprise value to revenue forward of Exagen Inc. – BOATS:XGN - TradingView
Exagen, Inc. Actuals & Estimates (NASDAQ:XGN) - TradingView
Exagen sets dates for second-quarter results, shares watched around Nasdaq listing - ad-hoc-news.de
E08A Forecast — Price Target — Prediction for 2027 - TradingView
XGN Forecast — Price Target — Prediction for 2027 - TradingView
XGN Initiates Coverage On Exagen -- Roth Capital Assigns Buy Rat - GuruFocus
XGN Q1 2026 Earnings: EPS Beat Drives Positive Stock MovementStrong Earnings Momentum - dars.gov.et
Exagen (XGN) Gains Buy Rating with $8 Price Target from Analyst - GuruFocus
Form 4 Exagen Inc For: 24 June By Investing.com - Investing.com Nigeria
Form 4 Exagen Inc For: 22 June By Investing.com - Investing.com Australia
Exagen (XGN) director Scott Kahn receives 37,500 stock options grant - Stock Titan
Exagen (XGN) director granted 37,500 stock options at $4.31 strike - Stock Titan
Exagen (XGN) director Frank Stokes receives 37,500 stock options at $4.31 - Stock Titan
Form 4 Exagen Inc For: 22 June - Investing.com India
Exagen StockSunday background on autoimmune diagnostics specialist - AD HOC NEWS
Exagen advances use of new RA biomarkers to refine patient risk assessment - Traders Union
XGN Q1 2026 Earnings: EPS Surprises with 15.15% Beat; Stock Gains 6.82%EPS Consistency Score - dars.gov.et
Exagen (XGN) Stock Draws Fresh Price Target Split After Analysts Trim Targets - Yahoo Finance
Exagen Inc (XGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exagen Inc (XGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
1.13%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):